Lilly Asia Ventures — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
San Diego, US
Board seatHongbo Lu· per SEC Form D · $5M raise · filed Aug 2020
San Francisco, US
BoardChristy Shaffer(Director)Chau Khuong(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)
Board seatHongbo Lu· per SEC Form D
Rgenta Therapeutics develops small molecule RNA modulation therapies through a discovery platform, aiming to create treatment options for patients with unmet medical needs across multiple therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Judith Li(Director)Debasish Roychowdhury(Director)Travis Wager(Co-founder, President and CSO)Sun Linghao(Director)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)
Board seatHongbo Lu· per SEC Form D · $38M raise · filed Mar 2021
BiotechFoster City, US
Weidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)David Fellows(Director)Jeffrey Kindler(Director)Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)
PartnerHongbo Lu· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.